Asim Siddiqui, PhD
Chief Technology Officer
With an extensive background in bioinformatics, systems and software engineering, next-generation sequencing, and cancer and prenatal diagnostics, Asim is responsible for building and overseeing NuMedii’s highly predictive drug discovery technology platform. Before NuMedii, he was in charge of product management and bioinformatics at several leading organizations including Natera, Life Technologies, Sirius Genomics, and the Genome Sciences Centre, part of the British Columbia Cancer Agency. An inventor on several patents, he has been an author on more than 30 peer-reviewed publications including several published in Science and Nature. Asim has a PhD in Bioinformatics from Oxford University, and a BA and a MA in Physics with honors from Cambridge University.
Craig Webb, PhD
Chief Scientific Officer
Craig is responsible for NuMedii’s scientific direction, partnerships and drug discovery. He is one of the founding scientists at the Van Andel Research Institute in Michigan and his research has resulted in the formation of four new companies in the areas of bioinformatics, molecular diagnostics and clinical trial coordination: TransMed Systems, Intervention Insights, The Center for Molecular Medicine and ClinXus. A former professor, Craig is an inventor on several patents, an author of numerous papers and book chapters, as well as an invited speaker at leading industry conferences. He has a BSc in Medical Biochemistry from the University of Surrey, a PhD in Biochemistry and Cell Biology from the University of East Anglia and has done post-doctoral work in molecular oncology at the National Cancer Institute.
Linda De Young, PhD
Head, Product Development
Linda bridges the connection between technology and drug development at NuMedii. She brings 20 years’ experience leading drug development programs for industry leading and start-up biotechnology and life science companies across a variety of platforms – small molecule, protein, polymer, cellular and antisense therapeutics – as well as a range of drug delivery devices. In addition to 10 years as a principal at Virtualizing Drug Development and IND Enabling Consulting, Linda held senior leadership positions at several companies focused on cardiovascular disease and oncology including AeroGen and Genentech. Linda has a BS in Biochemistry from the UC Davis, a PhD in Pharmaceutical Chemistry from UC San Francisco, and was a Postdoctoral Fellow, Department of Chemistry and Biochemistry, UC Santa Cruz.